The Cold Chain's Evolution

The pharmaceutical cold chain—the portion of the industry operating and advancing technological advances in temperature-sensitive transport, pallets, data loggers, sensors, and even new developments in freight services—is an all-encompassing topic, for sure.

The April issue of Pharmaceutical Commerce attempts to keep pace with the sector's accelerated activity, headlined by Nick Basta’s feature exploring cold-chain product distribution services and approaches—efforts that are continuing to experience success due to their evolution with the times.

“… Clients of cold chain services can rely on increasingly sophisticated packaging, containerization, and delivery technologies,” wrote Basta. “Vendors are building out more options for delivering products safely and securely, and while regulatory screws continue to tighten around shipment documentation and sustainability and environmental restrictions, new technologies offer alternative pathways to compliance. All in all, it makes for a lively market for investment in vendor growth.”

In that same breath, artificial intelligence (AI) in particular—albeit perhaps still a buzzword—has helped optimize the pharma transport process, as Pharma Commerce also explores in April. In a guest feature, Purav Gandhi of Healthark Insights notes that there is no doubt that pharma logistics is a complicated machine, but AI can streamline processes by filling in the gaps as it relates to such areas as dynamic route planning; real-time tracking; cost-efficiency optimization; advanced temperature reporting; regulatory compliance monitoring; and predictive analytics.

On another note, speaking of regulations, most would agree that the Inflation Reduction Act is a challenging one to navigate for many industries. In the pharma R&D space, this sentiment is no different. In a feature this month, Model N’s Jesse Mendelsohn reminds on how the advancement of promising, lifesaving drugs requires significant R&D investments. On average, new molecular entities cost $2.3 billion each to develop, largely funded by existing drug sales. But, meanwhile, pharma companies are under increasing pressure from the government to reduce prescription drug prices, which, in turn, presents a significant hurdle to maintaining the R&D pipeline.

Our April issue also provides expert commentary on behalf of Google Cloud, PAXAFE, Almac Pharma Services, McKesson, and, of course, our esteemed columnists.

Thanks for reading.

— Mike Hennessy Jr., President and CEO, MJH Life Sciences